39 research outputs found
Divergent Effects of Human Cytomegalovirus and Herpes Simplex Virus-1 on Cellular Metabolism
Viruses rely on the metabolic network of the host cell to provide energy and macromolecular precursors to fuel viral replication. Here we used mass spectrometry to examine the impact of two related herpesviruses, human cytomegalovirus (HCMV) and herpes simplex virus type-1 (HSV-1), on the metabolism of fibroblast and epithelial host cells. Each virus triggered strong metabolic changes that were conserved across different host cell types. The metabolic effects of the two viruses were, however, largely distinct. HCMV but not HSV-1 increased glycolytic flux. HCMV profoundly increased TCA compound levels and flow of two carbon units required for TCA cycle turning and fatty acid synthesis. HSV-1 increased anapleurotic influx to the TCA cycle through pyruvate carboxylase, feeding pyrimidine biosynthesis. Thus, these two related herpesviruses drive diverse host cells to execute distinct, virus-specific metabolic programs. Current drugs target nucleotide metabolism for treatment of both viruses. Although our results confirm that this is a robust target for HSV-1, therapeutic interventions at other points in metabolism might prove more effective for treatment of HCMV
Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis: 1-year results from MOBILE
Influence of baseline patient characteristics on response to one-monthly and daily oral ibandronate therapy: 2-year findings from MOBILE
The MOBILE study long-term extension: progressive improvements in efficacy with oral ibandronate (1500mg) when administered monthly
Oral ibandronate (150 mg) continues to be effective and well tolerated when administered monthly: the mobile study long-term extension
Clinical comparison in BMD gains with monthly oral ibandronate (150 mg) and weekly oral alendronate (70 mg) : results from the MOTION study
Monthly oral ibandronate is at least as effective as daily oral ibandronate in increasing hip BMD in postmenopausal osteoporosis : 1-year results from mobile
peer reviewe